Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non myeloablative "mini transplants".

S Giralt1, I Khouri, R Champlin

  • 1University of Texas MD Anderson Cancer Center, Houston, USA.

Cancer Treatment and Research
|May 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Blood cancer journal·2025
Same author

Unveiling two millennia of ecosystem changes in the Azores through elementome trajectory analysis.

Ecological indicators·2025
Same author

A ∼5000 year multiproxy record of summer climate in NE Greenland.

The Science of the total environment·2023
Same author

Ecology of the collapse of Rapa Nui society.

Proceedings. Biological sciences·2020
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2017
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Graft-versus-leukemia therapy shows promise as a primary treatment for hematologic malignancies, potentially avoiding myeloablative therapy. Further research is needed to overcome graft-versus-host disease (GVHD) and expand its application.

Area of Science:

  • Hematology
  • Immunotherapy
  • Oncology

Background:

  • Allogeneic progenitor cell transplantation is a curative option for hematologic malignancies.
  • Relapses after transplantation can occur, necessitating further treatment strategies.
  • Graft-versus-leukemia (GVL) effect is a key mechanism in successful transplantation.

Purpose of the Study:

  • To explore the potential of GVL induction as a primary therapy for hematologic malignancies without myeloablative conditioning.
  • To identify patient populations, such as the elderly or those with comorbidities, who could benefit from this approach.
  • To address the challenge of graft-versus-host disease (GVHD) in non-myeloablative settings.

Main Methods:

  • Utilizing non-myeloablative chemotherapy, such as fludarabine combinations, to achieve immunosuppression for engraftment.

Related Experiment Videos

  • Administering graded doses of donor lymphocytes to mediate GVL without rejection.
  • Investigating methods to diminish GVHD, including T-cell depletion and gene-modified T-cells.

    • Main Results:

    • Non-myeloablative chemotherapy with fludarabine combinations allows for engraftment of allogeneic progenitor cells.
    • Graded doses of donor lymphocytes can be administered to induce GVL.
    • GVHD remains a significant obstacle, even with reduced intensity conditioning.

    Conclusions:

    • Non-myeloablative GVL induction therapy offers a potentially less toxic alternative to conventional myeloablative transplantation.
    • This approach may expand the eligibility for stem cell transplantation to older or medically compromised patients.
    • Further strategies are required to mitigate GVHD and optimize GVL therapy for hematologic malignancies.